(Q43582605)

24 November 2017

title

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer (English)

1 reference

24 November 2017

1 reference

1 reference

5

Mark F Munsell

1 reference

24 November 2017

Janos L Tanyi

1

1 reference

24 November 2017

Judith A Smith

2

1 reference

24 November 2017

Lafit Ramos

3

1 reference

24 November 2017

Crystal L Parker

4

1 reference

24 November 2017

Judith K Wolf

6

1 reference

24 November 2017

language of work or name

English

0 references

publication date

17 May 2009

1 reference

24 November 2017

1 reference

24 November 2017

volume

114

1 reference

24 November 2017

issue

2

1 reference

24 November 2017

page(s)

219-224

1 reference

24 November 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Adriamycin. A new anticancer drug with significant clinical activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Role of pegylated liposomal doxorubicin in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Second-line chemotherapy for recurrent carcinoma of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Sterically stabilized liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

The cutaneous histopathology of chemotherapeutic reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.007

10.1016/J.YGYNO.2009.04.007

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference